One of the key strengths of this study is the comprehensive inclusion of a wide range of antidiabetic agents, including GLP-1 receptor agonists, insulin analogs, metformin, and pioglitazone, allowing for a thorough evaluation of their relative efficacy and safety in AD. The gene discussed is GLP1R; the disease is Alzheimer disease.